Geron Corporation GERN
0.99 USD -0.03 (-2.55%)
At closeNov 13, 2026, 5:40 AM EST
0.99 0.00 -0.42%
Pre-market · Nov 13, 5:40 AM ET
0.9613 Day range 1.02
0.84 52-week range 2.01
- YTD
- -24.70%
- 1 year
- -19.84%
News
marketbeat.com Geron Targets Germany Launch and Deals as RYTELO Sales Grow Geron NASDAQ: GERN is focusing on expanding U.S. use of its blood cancer drug RYTELO, preparing for a commercial sale in Germany and evaluating potential deals after discontinuing a late-stage trial…
benzinga.com Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six…
benzinga.com Geron Q3 2026 Earnings Call Transcript Geron (NASDAQ:GERN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…
benzinga.com Wedbush Maintains Outperform on Geron, Lowers Price Target to $5 Wedbush analyst Robert Driscoll maintains Geron (NASDAQ:GERN) with a Outperform and lowers the price target from $6 to $5.
benzinga.com Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth Geron stock plunges as the company halts its Phase 3 IMpactMF trial, refocusing its resources on commercial hematology and global expansion.
benzinga.com Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings U.S. stocks were mixed; Dow and S&P 500 rose while Nasdaq slipped. Brinker beat estimates and raised guidance; oil jumped 3.4%.